243 related articles for article (PubMed ID: 11248077)
1. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
De Windt LJ; Lim HW; Bueno OF; Liang Q; Delling U; Braz JC; Glascock BJ; Kimball TF; del Monte F; Hajjar RJ; Molkentin JD
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3322-7. PubMed ID: 11248077
[TBL] [Abstract][Full Text] [Related]
2. Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy.
Zhang W
Cardiovasc Res; 2002 Feb; 53(2):294-303. PubMed ID: 11827679
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibition and cardiac hypertrophy: a matter of balance.
Leinwand LA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):2947-9. PubMed ID: 11248009
[No Abstract] [Full Text] [Related]
4. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.
Taigen T; De Windt LJ; Lim HW; Molkentin JD
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1196-201. PubMed ID: 10655507
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
De Windt LJ; Lim HW; Taigen T; Wencker D; Condorelli G; Dorn GW; Kitsis RN; Molkentin JD
Circ Res; 2000 Feb; 86(3):255-63. PubMed ID: 10679475
[TBL] [Abstract][Full Text] [Related]
6. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli.
Nakayama H; Bodi I; Maillet M; DeSantiago J; Domeier TL; Mikoshiba K; Lorenz JN; Blatter LA; Bers DM; Molkentin JD
Circ Res; 2010 Sep; 107(5):659-66. PubMed ID: 20616315
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin and beyond: cardiac hypertrophic signaling.
Molkentin JD
Circ Res; 2000 Oct; 87(9):731-8. PubMed ID: 11055975
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Sussman MA; Lim HW; Gude N; Taigen T; Olson EN; Robbins J; Colbert MC; Gualberto A; Wieczorek DF; Molkentin JD
Science; 1998 Sep; 281(5383):1690-3. PubMed ID: 9733519
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin Aβ-Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy.
Li X; Li J; Martinez EC; Froese A; Passariello CL; Henshaw K; Rusconi F; Li Y; Yu Q; Thakur H; Nikolaev VO; Kapiloff MS
Circulation; 2020 Sep; 142(10):948-962. PubMed ID: 32611257
[TBL] [Abstract][Full Text] [Related]
10. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
11. Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
Zou Y; Yao A; Zhu W; Kudoh S; Hiroi Y; Shimoyama M; Uozumi H; Kohmoto O; Takahashi T; Shibasaki F; Nagai R; Yazaki Y; Komuro I
Circulation; 2001 Jul; 104(1):102-8. PubMed ID: 11435346
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy.
Shimoyama M; Hayashi D; Takimoto E; Zou Y; Oka T; Uozumi H; Kudoh S; Shibasaki F; Yazaki Y; Nagai R; Komuro I
Circulation; 1999 Dec; 100(24):2449-54. PubMed ID: 10595959
[TBL] [Abstract][Full Text] [Related]
13. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.
Li J; Kritzer MD; Michel JJ; Le A; Thakur H; Gayanilo M; Passariello CL; Negro A; Danial JB; Oskouei B; Sanders M; Hare JM; Hanauer A; Dodge-Kafka K; Kapiloff MS
Circ Res; 2013 Jan; 112(1):128-39. PubMed ID: 22997248
[TBL] [Abstract][Full Text] [Related]
14. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
Lu CC; Xu YQ; Wu JC; Hang PZ; Wang Y; Wang C; Wu JW; Qi JC; Zhang Y; Du ZM
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):747-55. PubMed ID: 23624753
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy.
Lim HW; De Windt LJ; Steinberg L; Taigen T; Witt SA; Kimball TR; Molkentin JD
Circulation; 2000 May; 101(20):2431-7. PubMed ID: 10821822
[TBL] [Abstract][Full Text] [Related]
16. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Molkentin JD; Lu JR; Antos CL; Markham B; Richardson J; Robbins J; Grant SR; Olson EN
Cell; 1998 Apr; 93(2):215-28. PubMed ID: 9568714
[TBL] [Abstract][Full Text] [Related]
17. Canstatin suppresses isoproterenol-induced cardiac hypertrophy through inhibition of calcineurin/nuclear factor of activated T-cells pathway in rats.
Sugiyama A; Okada M; Yamawaki H
Eur J Pharmacol; 2020 Mar; 871():172849. PubMed ID: 31843516
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Takeda Y; Yoneda T; Demura M; Usukura M; Mabuchi H
Circulation; 2002 Feb; 105(6):677-9. PubMed ID: 11839620
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension.
Murat A; Pellieux C; Brunner HR; Pedrazzini T
J Biol Chem; 2000 Dec; 275(52):40867-73. PubMed ID: 11016940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
